Jasper Therapeutics Inc (NASDAQ:JSPR – Get Rating) – Equities research analysts at Oppenheimer lowered their FY2022 EPS estimates for Jasper Therapeutics in a research report issued to clients and investors on Monday, March 21st. Oppenheimer analyst J. Olson now expects that the company will earn ($1.18) per share for the year, down from their previous […]